Professor Leonie Young is working to determine whether some secondary breast cancers that have spread to the brain could be treated with drugs called PARP inhibitors. She hopes that more people could benefit from this type of treatment.

Professor Janet Brown wants to determine if combining an immunotherapy drug avelumab with another drug, radium-233, could make the treatment more effective. She hopes this combination will improve the immune response to secondary breast cancer in the bone and at other sites in the body.

It’s thought that turning on the androgen receptor in some oestrogen receptor positive (ER+) breast cancers could help stop tumour growth. Dr Violeta Serra is investigating this theory further and is testing whether the androgen receptor could be a new treatment target.

Professor Simak Ali and Dr Lesley-Ann Martin are investigating how proteins called CDKs play a part in cancer’s resistance to palbociclib – a drug used to treat oestrogen receptor positive (ER+) secondary breast cancer. He is exploring whether blocking a protein called CDK7 could be a new way to treat tumours that have become resistant to palbociclib.

New ways to treat breast cancer that has spread to the bones are urgently needed. Professor Ingunn Holen is investigating the effect of the drug palbociclib on the spread of breast cancer to bone. She aims to find new treatment combinations to improve options available for patients.  

Dr Leo Carlin, along with Dr Seth Coffelt and Dr Frederic Fercoq, wants to understand how breast cancer cells manipulate the immune systemin the lung. He is hoping to use the results of this research to improve immunotherapy treatment for breast cancer.